Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855379 | 0.92 | MAPT (0.52) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL16246347 | 0.91 | MAOB (0.50) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL30375567 | 0.91 | MAOB (0.50) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL30789227 | 0.79 | MAOB (0.56) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL14616693 | 0.79 | MAOB (0.56) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL14178903 | 0.78 | CYP3A4 (0.63) | MAPTSMN1; SMN2L3MBTL1MAOBLMNA | |
| SCHEMBL21217354 | 0.78 | PDE4A (0.57) | SMN1; SMN2KCNA3HPGDCA9 | |
| SCHEMBL19267889 | 0.78 | SMN1; SMN2 (0.67) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 | |
| SCHEMBL10339706 | 0.78 | CYP3A4 (0.56) | MAPTSMN1; SMN2KCNA3LMNAHPGD | |
| SCHEMBL658101 | 0.78 | MAOB (0.61) | MAPTCYP2C9CYP2C19SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111836808-B | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising the same as active ingredient | 欧斯特奥纽罗根有限公司 | 2023-04-28 | — | — | CN | disclosed |
| EP-3760626-B1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | OSTEONEUROGEN INC (KR) | 2022-05-18 | — | — | EP | disclosed |
| EP-3760626-A1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | Osteoneurogen Inc. (KR) | 2021-01-06 | — | — | EP | disclosed |
| CN-111836808-A | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising same as active ingredient | 欧斯特奥纽罗根有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | OSTEONEUROGEN INC. (KR) | 2019-08-29 | — | — | US | disclosed |
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | OSTEONEUROGEN INC. (KR) | 2019-08-06 | — | — | US | disclosed |
| WO-2017146332-A1 | NOVEL USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING FIBROSIS BY USING EPITHELIAL-MESENCHYMAL TRANSITION INHIBITORY ACTIVITY THEREOF | (주)오스티오뉴로젠 | 2017-08-31 | — | — | WO | disclosed |
| US-6025387-A | Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease | DONG A PHARMACEUTICAL CO., LTD. (KR) | 2000-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | CYP7A1, NR1H3, CES1 | MAPT 4809/4885CYP2C9 330/4885CYP2C19 411/4885 |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | VIM, HNF4A, CDH1 | MAPT 3277/4885CYP2C9 582/4885CYP2C19 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.